Menu

Inosine

Also known as: Hypoxanthine riboside

A purine nucleoside whose urate-raising action did not deliver the hoped-for Parkinson disease benefit.

An unlabeled glass dish of fine ivory powder on warm paper beside an ink-green paper fold.
Editorial illustration

Inosine is a purine nucleoside that can raise urate. In the SURE-PD3 trial it did not slow early Parkinson disease, and kidney stones occurred more often. A biochemical role in energy metabolism should not be read as proof that a supplement improves exercise performance.1, 3, 4

  • The earlier 75-person Parkinson trial primarily assessed safety, tolerability and urate elevation, not definitive disease modification.2
  • The subsequent 298-person phase 3 trial stopped early for futility.3
  • A small crossover trial in male cyclists found no improvement in its aerobic or short-power tests.4

What is Inosine?

Inosine participates in purine biology and RNA-related processes. That physiological role is different from adding an isolated oral ingredient. This guide concerns inosine itself, rather than treating every similarly named nucleotide or combination medicine as interchangeable.1, 2, 4

Where it comes from

Natural sources

  • An endogenous purine-metabolism intermediate and a component of RNA biology.

How it's made

An isolated ingredient is not equivalent to the body's regulated production and use of inosine.

What it does in products

  • Oral ingredient studied for athletic performance
  • Investigational oral urate precursor

Benefits

Parkinson disease modification was not demonstrated

insufficient evidence

Successful urate elevation was not a successful clinical treatment in the phase 3 study.2, 3

SURE-PD3 enrolled adults with early disease and low baseline urate. Its primary progression outcome and secondary efficacy measures did not favor inosine. This negative treatment result is more decision-relevant than the earlier biomarker rationale.

Exercise-performance claims lack convincing support

insufficient evidence

The cited exercise experiment does not establish an ergogenic benefit.4

Ten competitive male cyclists received 5 g/day for five days in a placebo crossover trial. Several performance measures were unchanged; one time-to-fatigue test was worse. This small, short, older study cannot settle every sport or longer exposure.

Evidence scope and limitations

Isolated oral inosine: the SURE-PD phase 2 and 3 program, one small cycling trial and biological background; not a comprehensive review of all inosine-containing medicines.

  • The Parkinson population does not establish safety for children, pregnancy or people with different urate/renal conditions.
  • The cycling trial was small, male-only, brief and published in 1996; no broad claim of proven sports benefit follows.
  • Primary abstracts were checked where full-text retrieval failed; unreported subgroup, interaction and long-term outcomes are not inferred.

Evidence last checked: 2026-10-23

Side effects & safety

Kidney stones (varies)SURE-PD3 reported 7.0 versus 1.4 events per 100 patient-years with inosine versus placebo. These are trial rates, not an individual's predicted risk.

Safety considerations

  • The cited trials are not a complete drug-interaction screen; FDA advises discussing supplements with a clinician or pharmacist.
  • Not for: The kidney-stone signal warrants particular caution when a person already has stone or urate-management concerns; these data do not establish safe self-treatment.
  • Not for: Do not replace established Parkinson care with a urate-raising supplement.
3, 5

Amounts studied & product use

These figures describe research or common product use, not a personal dose or treatment recommendation.

In supplement studies and products

Research exposures are not personal dosing advice. The phase 2 trial used 500-mg capsules titrated to laboratory urate targets, with up to two capsules three times daily; it involved monitoring. The exercise trial used 5 g/day for five days. Neither protocol supplies a general wellness dose.

2, 4

Regulatory status

  • FDA does not preapprove dietary supplements as it does drugs. Supplement sale or a clinical-trial registration does not establish an approved Parkinson treatment, and this review does not determine the legal status of every inosine product.
5

A phase 2 green light was not the final answer

The early study asked whether researchers could raise urate with acceptable tolerability. Its conclusion supported a larger test; it was not a guarantee that the treatment would work.

The editorial distinction is between changing a proposed target and improving an outcome patients experience. The later negative trial belongs beside the biological explanation, not in a footnote beneath a positive antioxidant claim.

2, 3, 1

Frequently asked questions

Does a higher uric-acid result mean inosine is working?

It may show the biochemical action, but cannot by itself demonstrate a health benefit. The Parkinson program illustrates why target engagement and useful treatment outcomes need separate tests.2, 3

The bottom line

A plausible pathway is not a reason to pursue higher urate; the clinical outcome and stone risk matter more.

References

  1. Srinivasan S, Torres AG, Ribas de Pouplana L. Inosine in Biology and Disease. Genes (2021) · other · PMID 33921764; DOI 10.3390/genes12040600; biological background review, not proof of supplement efficacy
  2. Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A, et al.. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurology (2014) · randomized trial · PMID 24366103; DOI 10.1001/jamaneurol.2013.5528; NCT00833690; original indexed abstract checked
  3. Parkinson Study Group SURE-PD3 Investigators, Schwarzschild MA, Ascherio A, et al.. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA (2021) · randomized trial · PMID 34519802; DOI 10.1001/jama.2021.10207; NCT02642393; primary abstract checked; full-text retrieval unavailable
  4. Starling RD, Trappe TA, Short KR, et al.. Effect of inosine supplementation on aerobic and anaerobic cycling performance. Medicine & Science in Sports & Exercise (1996) · randomized trial · PMID 8883009; DOI 10.1097/00005768-199609000-00017; original indexed abstract checked
  5. Questions and Answers on Dietary Supplements. U.S. Food and Drug Administration · government guidance · Undated agency resource; current premarket-approval, claims and professional-consultation framework checked October 23, 2026

Revision history

  1. Initial AI-assisted source compilation with claim-level citations, formulation distinctions and explicit evidence limitations; not independent medical review.